Test ID: KRAS7
KRAS Mutation Analysis, 7 Mutation Panel, Colorectal
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Prognostic markers for cancer patients treated with epidermal growth factor receptor-targeted therapies
Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SLRVW | Slide Review | No | Yes |
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
When this test is ordered, Slide Review will always be performed at an additional charge.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
Polymerase Chain Reaction (PCR) Analysis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
KRAS Mutation Analysis, Colorectal
Aliases Lists additional common names for a test, as an aid in searching
Cetuximab (Erbitux)
Erbitux (Cetuximab)
Patiumumab (Vectibix)
Vectibix (Patiumumab)
RAS
Erbitux (Cetuximab)
Patiumumab (Vectibix)
Vectibix (Patiumumab)
RAS
External
link
PDF
document
Excel
document
Word
document